«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

26卷

期数:

2020年01期

页码:

35-38

栏目:

临床医学

出版日期:

2020-04-06

文章信息/Info

Title:

The effects of Ticagrelor and Clopidogrel on platelet aggregation rate, hemodynamics and immunologic function in patients with acute coronary syndrome after PCI

文章编号:

1006-8147(2020)01-0035-04

作者:

王 珂; 石继红; 魏振衡

（周口市中心医院心内三科 ,周口466000）

Author(s):

WANG Ke;  SHI Ji-hong;  WEI Zhen-heng

（Department of Heart 3 ，Zhoukou Central Hospital, Zhoukou 466000,China）

关键词:

急性冠脉综合征; 替格瑞洛; 氯吡格雷; 血小板聚集率; 血流动力学; 免疫功能

Keywords:

acute coronary syndrome; Ticagrelor; Clopidogrel; platelet aggregation rate; hemodynamics; immunologic function

分类号:

R541.4

DOI:

-

文献标志码:

A

摘要:

目的：探讨替格瑞洛、氯吡格雷对急性冠脉综合征（ACS）患者经皮冠状动脉介入治疗（PCI）术后血小板聚集率、血流动力学及免疫功能的影响。方法：选取本院心血管内科收治的124例ACS患者作为研究对象，随机分为观察组（n=62）和对照组（n =62），观察组给予替格瑞洛治疗，对照组给予氯吡格雷治疗，观察比较两组患者治疗前后小板聚集率、血流动力学指标、免疫功能指标变化情况和出血情况。结果：治疗后，两组患者血小板聚集率（PAV）均低于治疗前（P＜0.05），且观察组明显低于对照组（P＜0.05）；治疗后，两组患者全血黏度（BV）、血浆粘度（PV）均低于治疗前（P＜0.05），观察组明显低于对照组（P＜0.05），而收缩期血流速度峰值（SPV），舒张期血流速度峰值（DPV），冠脉血流储备（CFVR）均高于治疗前（P＜0.05），且观察组明显高于对照组（P＜0.05）；治疗后，两组患者CD3+、CD4+水平均高于治疗前（P＜0.05），观察组明显高于对照组（P＜0.05），而CD8+水平低于治疗前（P＜0.05），观察组低于对照组（P＜0.05）；两组患者总出血事件发生率比较差异无统计学意义（P＞0.05）。结论：替格瑞洛能有效抑制ACS患者PCI术后血小板凝集，改善血流动力学和免疫功能，安全性高。

Abstract:

Objective: To investigate the effects of Ticagrelor and Clopidogrel on platelet aggregation rate, hemodynamics and immunologic function in patients with acute coronary syndrome(ACS) after percutaneous coronary intervention(PCI). Methods：One hundred and twenty-four patients with ACS were randomly divided into observation group(n =62) and control group (n =62), the observation group was treated with Ticagrelor and the control group with Clopidogrel, and the platelet aggregation rate, hemodynamic index, immune function index and occurrence of Bleeding conditionwere observed and compared between the two groups before and after treatment. Results：After treatment, the platelet aggregation rate(PAV) of the two groups was lower than that before treatment (P＜0.05), and the observation group was significantly lower than the control group (P＜0.05); after treatment, the whole blood viscosity (BV) and plasma viscosity (PV) of the two groups were lower than those before treatment (P＜0.05), the observation group was significantly lower than the control group(P＜0.05), while the peak systolic velocity(SPV), peak diastolic velocity (DPV) and coronary flow velocityreserve(CFVR) were higher than those before treatment (P＜0.05),andthe observation group was significantly higher than the control group (P＜0.05); after treatment, the levels of CD3+ and CD4 + in the two groups were higher than those before treatment(P＜0.05), the level of CD8 + in the observation group was significantly higher than that in the control group (P＜0.05), and the levelof CD8+ in the observation group was lower than that before treatment (P＜0.05); there was no significant difference in the total incidence of bleeding events between the two groups(P＞0.05). Conclusion：Tigrelol can effectively inhibit platelet aggregation after PCI in ACS patients, and improve hemodynamics and immunologic function with high safety.

参考文献/References:

[1] Sanchis-Gomar F, Perez-Quilis C, Leischik R A. Epidemiology of coronary heart disease and acute coronary syndrome[J]. Ann Transl Med, 2016,4(13):256
[2] Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (Antarctic): an open-label, blinded-endpoint, randomised controlled superiority trial[J]. Lancet, 2016, 388(155):2015
[3] Wang Y, Su G, Zhou Y, et al. Characteristics and prognosis in patients of acute coronary syndrome combining anemia after percutaneous coronary intervention[J]. Circ J, 2016, 31(8):732
[4] Wang H, Wang X. Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome[J].Ther Clin Risk Manag, 2016,12(1):1101
[5] Sahlén A, Varenhorst C, Lagerqvist B, et al. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)[J]. Eur Heart J Cardiovasc Pharmacother, 2016,2(1):5
[6] Davlouros P, Xanthopoulou I, Goudevenos J, et al. Contemporary antiplatelet treatment in acute coronary syndrome patients with impaired renal function undergoing percutaneous coronary intervention[J]. Cardiol, 2017,138(3):186
[7] Li M, Wang H, Xuan L, et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome[J]. Medicine, 2017, 96(14):e6553
[8] Caruso R, Rocchiccioli S, Gori A M, et al. Inflammatory and antioxidant pattern unbalance in“Clopidogrel-Resistant” patients during acute coronary syndrome[J]. Mediators Inflamm,2015,2015:710123
[9] Zhi H I, Zhang Y C, Xie Y Q, et al. Clinical efficacy and safety of ticagrelor in acute coronary syndrome patients receiving percutaneous coronary intervention[J]. J Interv Cardiol,2015,23(8):446
[10] Tan Q, Jiang X, Huang S, et al. The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis[J]. PLoS One, 2017,12(5):e0177872
[11] Li S X. Effect of different drug treatments on platelet aggregation rate and prognosis in patients with acute coronary syndrome after PCI[J]. J Beth Mili Med Coll, 2017,15(6):750
[12] Wijnbergen I, Van’t Veer M, Lammers J, et al. Absolute coronary blood flow measurement and microvascular resistance in ST-elevation myocardial infarction in the acute and subacute phase[J].Cardiovasc Revasc Med, 2016,17(2):81
[13] Asher E, Frydman S, Katz M, et al. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibitionin Acute Coronary Syndrome-the CHEERS study. For The PLATIS(Platelets and Thrombosis in Sheba)Study Group[J]. Thromb Haemost, 2017,117(4):727
[14] Luo Y, Chen Y M. Effects of different doses of ticagrelor on coronary blood flow, inflammatory response and myocardial enzymes in patients with acute myocardial infarction after PCI[J]. J Hainan Med Coll, 2018,24(2):161
[15] Cao L, Bian Y F. Effect of ticagrelor on serum uric acid level and its anti-inflammatory effect in acute coronary syndrome patients after PCI[J]. Hosp Pharm, 2017, 37(15):1498
[16] Guo Y, Zhuang X D, Fei F F, et al. Immunosuppressive effect of ticagrelor, a novel antiplatelet drug, on dendritic cell function[J].Med Sci, 2015,36(3):366

相似文献/References:

[1]张程征,袁如玉.女性早发急性冠脉综合征血压变异性的研究[J].天津医科大学学报,2014,20(02):127.
　ZHANG Cheng-zheng,YUAN Ru-yu.Blood pressure variability in female patients with premature acute coronary syndrome[J].Journal of Tianjin Medical University,2014,20(01):127.
[2]孙丽丽,李广平,刘相丽,等. ACS患者血清脂蛋白相关磷脂酶A2水平与GRACE评分的相关性 [J].天津医科大学学报,2015,21(04):324.
　SUN Li-li,LI Guang-ping,LIU Xiang-li,et al.Correlation between lipoprotein-associated phospholipase A2 levels and global registey of acute coronary event score in patients with acute coronary syndromes[J].Journal of Tianjin Medical University,2015,21(01):324.
[3]米怀雪,张申,马宪鲁.替格瑞洛在冠脉搭桥术治疗急性ST段抬高性心肌梗死的临床疗效[J].天津医科大学学报,2018,24(02):165.
　MI Huai-xue,ZHANG Shen,MA Xian-lu.Clinical effect of ticagrelor in the treatment of acute ST segment elevation myocardial infarction in patients undergoing coronary artery bypass grafting[J].Journal of Tianjin Medical University,2018,24(01):165.
[4]刘燕霞,刘相丽.情绪障碍对ACS患者NLR水平和GRACE评分危险分层的影响[J].天津医科大学学报,2019,25(03):267.
　LIU Yan-xia,LIU Xiang-li.Effects of mood disorders on NLR and risk stratification of GRACE scores in ACS patients[J].Journal of Tianjin Medical University,2019,25(01):267.
[5]马岳,魏鳌,胡越成,等.血小板-淋巴细胞比值与冠状动脉病变复杂性的相关分析[J].天津医科大学学报,2019,25(06):595.
　MA Yue,WEI Ao,HU Yue-cheng,et al.Correlation between platelet-to-lymphocyte ratio and the complexity of coronary artery disease[J].Journal of Tianjin Medical University,2019,25(01):595.
[6]郝增光,韩兆帅,葛慧敏.血小板与淋巴细胞比值评估合并多支血管病变的急性心肌梗死患者预后的价值[J].天津医科大学学报,2021,27(02):150.
　HAO Zeng-guang,HAN Zhao-shuai,GE Hui-min.The value of platelet to lymphocyte ratio in evaluating the prognosis of patients with acute myocardial infarction combined with multivessel disease[J].Journal of Tianjin Medical University,2021,27(01):150.

备注/Memo

备注/Memo:

作者简介 王珂（1983-），男，主治医师，学士，研究方向：心血管内科；E-mail:xiaoyaochunfen@163.com。

常用功能

更新日期/Last Update: 2020-04-16